BioToxTech Co

BioToxTech Co Stock-Based Compensation

The Stock-Based Compensation (SBC) of BioToxTech Co (086040.KQ) as of Nov 12, 2026 is 133.64 M KRW. In the previous year, Stock-Based Compensation (SBC) was 290.34 M KRW — a change of -53.97% (lower).

Stock-Based Compensation

133.64 MKRW

YoY

-53.97%

Last updated:

Stock-Based Compensation (SBC) of BioToxTech Co is 2025 133.64 M KRW. Stock-Based Compensation (SBC) of BioToxTech Co was 2024 290.34 M KRW. It decreases by -53.97% lower compared to the previous year.

The BioToxTech Co Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2020
393.13 M KRW
Jan 1, 2021
69.32 M KRW
Jan 1, 2022
132.80 M KRW
Jan 1, 2023
323.04 M KRW
Jan 1, 2024
290.34 M KRW
Jan 1, 2025
133.64 M KRW
The BioToxTech Co Stock-Based Compensation history
YEARStock-Based CompensationYoY
133.64 MKRW-53.97%
290.34 MKRW-10.12%
323.04 MKRW+143.26%
132.80 MKRW+91.56%
69.32 MKRW-82.37%
393.13 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Stock-Based Compensation (SBC) of BioToxTech Co is 133.64 M KRW in 2025.

Stock-Based Compensation (SBC) of BioToxTech Co changed from 290.34 M KRW to 133.64 M KRW, representing a -53.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s BioToxTech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BioToxTech Co

All Key Metrics — BioToxTech Co